An allosteric modulator is a ligand that binds to an allosteric site on the receptor and changes receptor conformation to produce increase (positive cooperativity) or decrease (negative cooperativity) in the binding or action of an orthosteric agonist (e.g., acetylcholine). Since the identification of gallamine as the first allosteric modulator of muscarinic receptors in 1976, this unique mode of receptor modulation has been intensively studied by many groups. This review summarizes over 30 years of research on the molecular mechanisms of allosteric interactions of drugs with the receptor and for new allosteric modulators of muscarinic receptors with potential therapeutic use. Identification of positive modulators of acetylcholine binding and function that enhance neurotransmission and the discovery of highly selective allosteric modulators are mile-stones on the way to novel therapeutic agents for the treatment of schizophrenia, Alzheimer's disease and other disorders involving impaired cognitive function.

Division of Neuroscience Research in Psychiatry University of Minnesota Medical School Minneapolis MN 55455 USA

Institute of Physiology Academy of Sciences of the Czech Republic Vídeňská 1083 142 00 Praha Czech Republic

Zobrazit více v PubMed

Dale H.H. The action of certain esters and ethers of choline and their relation to muscarine. J. Pharmacol. 1914;6:147–190.

Loewi O. Über humorale Übertragbarkeit der Herznervenwirkung. I. Pflügers Archiv. 1921;189:239–242. doi: 10.1007/BF01738910. DOI

Bonner T.I., Buckley N.J., Young A.C., Brann M.R. Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987;237:527–532. PubMed

Caulfield M.P. Muscarinic receptors--characterization, coupling and function. Pharmacol. Ther. 1993;58:319–379. PubMed

Levey A.I. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 1993;52:441–448. PubMed

Felder C.C., Porter A.C., Skillman T.L., Zhang L., Bymaster F.P., Nathanson N.M., Hamilton S.E., Gomeza J., Wess J., McKinzie D.L. Elucidating the role of muscarinic receptors in psychosis. Life Sci. 2001;68:2605–2613. PubMed

Langmead C.J., Watson J., Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol.Ther. 2008;117:232–243. PubMed

Brito G.N., Davis B.J., Stopp L.C., Stanton M.E. Memory and the septo-hippocampal cholinergic system in the rat. Psychopharmacology (Berl) 1983;81:315–320. doi: 10.1007/BF00427569. PubMed DOI

Meck W.H., Church R.M., Wenk G.L., Olton D.S. Nucleus basalis magnocellularis and medial septal area lesions differentially impair temporal memory. J. Neurosci. 1987;7:3505–3511. PubMed PMC

Christie J.E., Shering A., Ferguson J., Glen A.I. Physostigmine and arecoline, effects of intravenous infusions in Alzheimer presenile dementia. Br. J. Psychiatry. 1981;138:46–50. PubMed

Bymaster F.P., McKinzie D.L., Felder C.C., Wess J. Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem.Res. 2003;28:437–442. PubMed

Wess J., Eglen R.M., Gautam D. Muscarinic acetylcholine receptors, mutant mice provide new insights for drug development. Nat. Rev. Drug Discov. 2007;6:721–733. PubMed

Caccamo A., Oddo S., Billings L.M., Green K.N., Martinez-Coria H., Fisher A., LaFerla F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49:671–682. PubMed

Jones C.K., Brady A.E., Davis A.A., Xiang Z., Bubser M., Tantawy M.N., Kane A.S., Bridges T.M., Kennedy J.P., Bradley S.R., Peterson T.E., Ansari M.S., Baldwin R.M., Kessler R.M., Deutch A.Y., Lah J.J., Levey A.I., Lindsley C.W., Conn P.J. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 2008;28:10422–10433. PubMed PMC

Perry E.K., Kilford L., Lees A.J., Burn D.J., Perry R.H. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann. Neurol. 2003;54:235–238. doi: 10.1002/ana.10639. PubMed DOI

Machová E., Jakubík J., Michal P., Oksman M., Iivonen H., Tanila H., Doležal V. Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice. Neurobiol.Aging. 2008;29:368–378. PubMed

Machová E., Rudajev V., Smycková H., Koivisto H., Tanila H., Dolezal V. Functional cholinergic damage develops with amyloid accumulation in young adult APPswe/PS1dE9 transgenic mice. Neurobiol.Dis. 2010;38:27–35. PubMed

Biel J.H., Nuhfer P.A., Hoya W.K., Leiser H.A., Abood L.G. Cholinergic blockade as an approach to the development of new psychotropic agents. Ann. N. Y. Acad. Sci. 1962;96:251–262. PubMed

Mego D.M., Omori J.M., Hanley J.F. Transdermal scopolamine as a cause of transient psychosis in two elderly patients. South.Med. J. 1988;81:394–395. PubMed

Dean B., Crook J.M., Opeskin K., Hill C., Keks N., Copolov D.L. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol. Psychiatry. 1996;1:54–58. PubMed

Dean B., Crook J.M., Pavey G., Opeskin K., Copolov D.L. Muscarinic1 and 2 receptor mRNA in the human caudate-putamen, no change in m1 mRNA in schizophrenia. Mol. Psychiatry. 2000;5:203–207. PubMed

Crook J.M., Dean B., Pavey G., Copolov D. The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci. 1999;64:1761–1771. PubMed

Crook J.M., Tomaskovic-Crook E., Copolov D.L., Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia, a study of the human hippocampal formation. Biol. Psychiatry. 2000;48:381–388. PubMed

Crook J.M., Tomaskovic-Crook E., Copolov D.L., Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia, a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am. J. Psychiatry. 2001;158:918–925. PubMed

Raedler T.J., Bymaster F.P., Tandon R., Copolov D., Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry. 2007;12:232–246. PubMed

Tzavara E.T., Bymaster F.P., Davis R.J., Wade M.R., Perry K.W., Wess J., McKinzie D.L., Felder C., Nomikos G.G. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission, relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J. 2004;18:1410–1412. PubMed

Kenakin T. Allosteric agonist modulators. J. Recept. Signal. Transduct. Res. 2007;27:247–259. PubMed

Clark A.L., Mitchelson F. The inhibitory effect of gallamine on muscarinic receptors. Br. J. Pharmacol. 1976;58:323–331. PubMed PMC

Stockton J.M., Birdsall N.J., Burgen A.S., Hulme E.C. Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol. 1983;23:551–557. PubMed

Nedoma J., Dorofeeva N.A., Tuček S., Shelkovnikov S.A., Danilov A.F. Interaction of the neuromuscular blocking drugs alcuronium, decamethonium, gallamine, pancuronium, ritebronium, tercuronium and d-tubocurarine with muscarinic acetylcholine receptors in the heart and ileum. Naunyn Schmiedebergs Arch. Pharmacol. 1985;329:176–181. doi: 10.1007/BF00501209. PubMed DOI

Nedoma J., Tucek S., Danilov A.F., Shelkovnikov S.A. Stabilization of antagonist binding to cardiac muscarinic acetylcholine receptors by gallamine and other neuromuscular blocking drugs. J. Pharmacol. Exp. Ther. 1986;236:219–223. PubMed

Waelbroeck M., Robberecht P., De Neef P., Christophe J. Effects of verapamil on the binding properties of rat heart muscarinic receptors, evidence for an allosteric site. Biochem. Biophys. Res. Commun. 1984;121:340–345. PubMed

Lai W.S., Ramkumar V., el-Fakahany E.E. Possible allosteric interaction of 4-aminopyridine with rat brain muscarinic acetylcholine receptors. J. Neurochem. 1985;44:1936–1942. PubMed

Kloog Y., Sokolovsky M. Allosteric interactions between muscarinic agonist binding sites and effector sites demonstrated by the use of bisquaternary pyridinium oximes. Life Sci. 1985;36:2127–2136. PubMed

Flynn D.D., Mash D.C. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine. J. Pharmacol. Exp. Ther. 1989;250:573–581. PubMed

Jooste E., Klafter F., Hirshman C.A., Emala C.W. A mechanism for rapacuronium-induced bronchospasm, M2 muscarinic receptor antagonism. Anesthesiology. 2003;98:906–911. PubMed

Hu J., el-Fakahany E.E. Allosteric interaction of dynorphin and myelin basic protein with muscarinic receptors. Pharmacology. 1993;47:351–359. PubMed

Dalton D.W., Tyers M.B. A comparison of the muscarinic antagonist actions of pancuronium and alcuronium. J. Auton. Pharmacol. 1982;2:261–266. PubMed

Jakubík J., Bačáková L., El-Fakahany E.E., Tuček S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 1997;52:172–179. PubMed

Lazareno S., Popham A., Birdsall N.J. Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes, identification of a second allosteric site. Mol. Pharmacol. 2000;58:194–207. PubMed

Lazareno S., Doležal V., Popham A., Birdsall N.J.M. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors, receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 2004;65:257–266. PubMed

Zlotos D.P., Buller S., Stiefl N., Baumann K., Mohr K. Probing the pharmacophore for allosteric ligands of muscarinic M2 receptors, SAR and QSAR studies in a series of bisquaternary salts of caracurine V and related ring systems. J. Med. Chem. 2004;47:3561–3571. PubMed

Proška J., Tuček S. Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. Mol. Pharmacol. 1994;45:709–717. PubMed

Ellis J., Huyler J., Brann M.R. Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem.Pharmacol. 1991;42:1927–1932. PubMed

Jakubík J., Bačáková L., el-Fakahany E.E., Tuček S. Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 1995;274:1077–1083. PubMed

Leppik R.A., Miller R.C., Eck M., Paquet J.L. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. Mol. Pharmacol. 1994;45:983–990. PubMed

Krejčí A., Tuček S. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. Mol. Pharmacol. 2001;60:761–767. PubMed

Huang X., Prilla S., Mohr K., Ellis J. Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor, more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phtha)] Mol. Pharmacol. 2005;68:769–778. PubMed

Matsui H., Lazareno S., Birdsall N.J. Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. Mol. Pharmacol. 1995;47:88–98. PubMed

Jakubík J., Krejčí A., Doležal V. Asparagine, valine, and threonine in the third extracellular loop of muscarinic receptor have essential roles in the positive cooperativity of strychnine-like allosteric modulators. J. Pharmacol. Exp. Ther. 2005;313:688–696. PubMed

Voigtländer U., Jöhren K., Mohr M., Raasch A., Tränkle C., Buller S., Ellis J., Höltje H., Mohr K. Allosteric site on muscarinic acetylcholine receptors, identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupie. Mol. Pharmacol. 2003;64:21–31. PubMed

Prilla S., Schrobang J., Ellis J., Höltje H., Mohr K. Allosteric interactions with muscarinic acetylcholine receptors, complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol. Pharmacol. 2006;70:181–193. PubMed

Tränkle C., Dittmann A., Schulz U., Weyand O., Buller S., Jöhren K., Heller E., Birdsall N.J.M., Holzgrabe U., Ellis J., Höltje H.D., Mohr K. Atypical muscarinic allosteric modulation, cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors. Mol. Pharmacol. 2005;68:1597–1610. PubMed

Lazareno S., Popham A., Birdsall N.J.M. Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol. Pharmacol. 2002;62:1492–1505. PubMed

Lanzafame A.A., Sexton P.M., Christopoulos A. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. Mol. Pharmacol. 2006;70:736–746. PubMed

Tränkle C., Mies-Klomfass E., Cid M.H., Holzgrabe U., Mohr K. Identification of a [3H]Ligand for the common allosteric site of muscarinic acetylcholine M2 receptors. Mol. Pharmacol. 1998;54:139–145. PubMed

Lysíková M., Fuksová K., Elbert T., Jakubík J., Tuček S. Subtype-selective inhibition of [methyl-3H]-N-methylscopolamine binding to muscarinic receptors by alpha-truxillic acid esters. Br. J. Pharmacol. 1999;127:1240–1246. PubMed PMC

Mohr K., Tränkle C., Holzgrabe U. Structure/activity relationships of M2 muscarinic allosteric modulators. Receptors Channels. 2003;9:229–240. PubMed

Birdsall N.J.M., Lazareno S. Allosterism at muscarinic receptors, ligands and mechanisms. Mini. Rev. Med. Chem. 2005;5:523–543. doi: 10.2174/1389557054023251. PubMed DOI

Lazareno S., Gharagozloo P., Kuonen D., Popham A., Birdsall N.J. Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors, radioligand binding studies. Mol. Pharmacol. 1998;53:573–589. PubMed

Lysíková M., Havlas Z., Tuček S. Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors, potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists. Neurochem Res. 2001;26:383–394. doi: 10.1023/A:1010951131496. PubMed DOI

Jöhren K., Höltje H. A model of the human M2 muscarinic acetylcholine receptor. J. Comput. Aided Mol. Des. 2002;16:795–801. PubMed

Jakubík J., Tuček S. Positive allosteric interactions on cardiac muscarinic receptors, effects of chemical modifications of disulphide and carboxyl groups. Eur. J. Pharmacol. 1995;289:311–319. PubMed

Huang X., Ellis J. Mutational disruption of a conserved disulfide bond in muscarinic acetylcholine receptors attenuates positive homotropic cooperativity between multiple allosteric sites and has subtype-dependent effects on the affinities of muscarinic allosteric ligands. Mol. Pharmacol. 2007;71:759–768. PubMed

Diaz-Arrastia R., Ashizawa T., Appel S.H. Endogenous inhibitor of ligand binding to the muscarinic acetylcholine receptor. J. Neurochem. 1985;44:622–628. PubMed

Maslinski W., Ryzewski J., Bartfai T. Rat thymocytes release a factor which inhibits muscarinic ligand binding. J. Neuroimmunol. 1988;17:275–285. PubMed

Fryer A.D., el-Fakahany E.E. An endogenous factor induces heterogeneity of binding sites of selective muscarinic receptor antagonists in rat heart. Membr.Biochem. 1989;8:127–132. PubMed

Frey W.H.2., Emory C.R., Wiebenga M.E., Saxena S., Cardelli D., Ala T.A., Tollefson G.D. Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain. Brain Res. 1994;655:153–160. PubMed

Fang Y.I., Suzuki T., Momose K. Partial purification of an endogenous inhibitor of muscarinic ligand binding. Biochem.Mol. Biol. Int. 1996;38:501–507. PubMed

Jacoby D.B., Gleich G.J., Fryer A.D. Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J. Clin. Invest. 1993;91:1314–1318. PubMed PMC

Kjome J.R., Swenson K.A., Johnson M.N., Bordayo E.Z., Anderson L.E., Klevan L.C., Fraticelli A.I., Aldrich S.L., Fawcett J.R., Venters H.D.J., Ala T.A., Frey W.H.2. Inhibition of antagonist and agonist binding to the human brain muscarinic receptor by arachidonic acid. J. Mol. Neurosci. 1998;10:209–217. PubMed

Frey W.H.2., Najarian M.M., Kumar K.S., Emory C.R., Menning P.M., Frank J.C., Johnson M.N., Ala T.A. Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor. Brain Res. 1996;714:87–94. PubMed

Fawcett J.R., Bordayo E.Z., Jackson K., Liu H., Peterson J., Svitak A., Frey W.H.2. Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants. Brain Res. 2002;950:10–20. PubMed

Ma L., Seager M.A., Wittmann M., Jacobson M., Bickel D., Burno M., Jones K., Graufelds V.K., Xu G., Pearson M., McCampbell A., Gaspar R., Shughrue P., Danziger A., Regan C., Flick R., Pascarella D., Garson S., Doran S., Kreatsoulas C., Veng L., Lindsley C.W., Shipe W., Kuduk S., Sur C., Kinney G., Seabrook G.R., Ray W.J. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc. Natl. Acad. Sci. USA. 2009;106:15950–15955. PubMed PMC

Shirey J.K., Brady A.E., Jones P.J., Davis A.A., Bridges T.M., Kennedy J.P., Jadhav S.B., Menon U.N., Xiang Z., Watson M.L., Christian E.P., Doherty J.J., Quirk M.C., Snyder D.H., Lah J.J., Levey A.I., Nicolle M.M., Lindsley C.W., Conn P.J. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J. Neurosci. 2009;29:14271–14286. PubMed PMC

Marlo J.E., Niswender C.M., Days E.L., Bridges T.M., Xiang Y., Rodriguez A.L., Shirey J.K., Brady A.E., Nalywajko T., Luo Q., Austin C.A., Williams M.B., Kim K., Williams R., Orton D., Brown H.A., Lindsley C.W., Weaver C.D., Conn P.J. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol. Pharmacol. 2009;75:577–588. PubMed PMC

Bridges T.M., Marlo J.E., Niswender C.M., Jones C.K., Jadhav S.B., Gentry P.R., Plumley H.C., Weaver C.D., Conn P.J., Lindsley C.W. Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. J. Med. Chem. 2009;52:3445–3448. PubMed PMC

Shirey J.K., Xiang Z., Orton D., Brady A.E., Johnson K.A., Williams R., Ayala J.E., Rodriguez A.L., Wess J., Weaver D., Niswender C.M., Conn P.J. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat. Chem. Biol. 2008;4:42–50. PubMed

Brady A.E., Jones C.K., Bridges T.M., Kennedy J.P., Thompson A.D., Heiman J.U., Breininger M.L., Gentry P.R., Yin H., Jadhav S.B., Shirey J.K., Conn P.J., Lindsley C.W. Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats. J. Pharm. Expert. Ther. 2008;327:941–953. PubMed PMC

Chan W.Y., McKinzie D.L., Bose S., Mitchell S.N., Witkin J.M., Thompson R.C., Christopoulos A., Lazareno S., Birdsall N.J.M., Bymaster F.P., Felder C.C. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl. Acad. Sci. USA. 2008;105:10978–10983. PubMed PMC

Nawaratne V., Leach K., Suratman N., Loiacono R.E., Felder C.C., Armbruster B.N., Roth B.L., Sexton P.M., Christopoulos A. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug) Mol. Pharmacol. 2008;74:1119–1131. PubMed

Nawaratne V., Leach K., Suratman N., Loiacono R.E., Felder C.C., Armbruster B.N., Roth B.L., Sexton P.M., Christopoulos A. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug) Mol. Pharmacol. 2008;74:1119–1131. PubMed

Jakubík J., Randáková A., El-Fakahany E.E., Doležal V. Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors. BMC Pharmacol. 2009;9:15. PubMed PMC

Goudsouzian N.G. Rapacuronium and bronchospasm. Anesthesiology. 2001;94:727–728. doi: 10.1097/00000542-200105000-00006. PubMed DOI

Jakubík J., Bačáková L., Lisá V., el-Fakahany E.E., Tuček S. Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc. Natl. Acad. Sci. USA. 1996;93:8705–8709. PubMed PMC

Sur C., Mallorga P.J., Wittmann M., Jacobson M.A., Pascarella D., Williams J.B., Brandish P.E., Pettibone D.J., Scolnick E.M., Conn P.J. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl. Acad. Sci. USA. 2003;100:13674–13679. PubMed PMC

Spalding T.A., Trotter C., Skjaerbaek N., Messier T.L., Currier E.A., Burstein E.S., Li D., Hacksell U., Brann M.R. Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol. Pharmacol. 2002;61:1297–1302. PubMed

Bradley S.R., Lameh J., Ohrmund L., Son T., Bajpai A., Nguyen D., Friberg M., Burstein E.S., Spalding T.A., Ott T.R., Schiffer H.H., Tabatabaei A., McFarland K., Davis R.E., Bonhaus D.W. AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology. 2009;58:365–373. PubMed

Spalding T.A., Ma J., Ott T.R., Friberg M., Bajpai A., Bradley S.R., Davis R.E., Brann M.R., Burstein E.S. Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine, evidence for three distinct modes of receptor activation. Mol. Pharmacol. 2006;70:1974–1983. doi: 10.1124/mol.106.024901. PubMed DOI

Lebon G., Langmead C.J., Tehan B.G., Hulme E.C. Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol. Pharmacol. 2009;75:331–341. PubMed PMC

Thomas R.L., Langmead C.J., Wood M.D., Challiss R.A.J. Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation. J. Pharmacol. Exp. Ther. 2009;331:1086–1095. PubMed PMC

Allosteric Modulation of Muscarinic Receptors by Cholesterol, Neurosteroids and Neuroactive Steroids

Current Advances in Allosteric Modulation of Muscarinic Receptors

Structural Insight into Specificity of Interactions between Nonconventional Three-finger Weak Toxin from Naja kaouthia (WTX) and Muscarinic Acetylcholine Receptors

Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors

On homology modeling of the M₂ muscarinic acetylcholine receptor subtype